Ultime notizie per Lovesac (NASDAQ:LOVE) Azioni

Lovesac

The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.

The Lovesac Co

LOVE GROUP GLOBAL LTD by LOVE GROUP GLOBAL LTD.

LOVE HEMP GROUP PLC by LOVE HEMP GROUP PLC

Love Hemp Group PLC

WIIM

CGTX

Cognition Therapeutics shares are trading higher after the company provided an update on a biomarker analysis from the Phase 2 SHINE study in mild-to-moderate Alzheimer's disease.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

News

Price Target

Reiteration

Analyst Ratings

ABEO

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

Northland Capital Markets analyst Ted Jackson downgrades Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) from Outperform to Market Perform and lowers the price target from $9 to $5.

Downgrades

Northland Capital Markets Downgrades Xos to Market Perform, Lowers Price Target to $5

WestPark Capital analyst Paul Rodriguez reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Hold.

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdings

Rosenblatt analyst Barton Crockett maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Buy and raises the price target from $7.7 to $10.3.

QUAD

Rosenblatt Maintains Buy on Quad/Graphics, Raises Price Target to $10.3

"Alarum's fourth quarter 2024 revenues are estimated at $7.5 million ±3% and Adjusted EBITDA for the fourth quarter 2024 is expected to range from $1.3 million to $1.7 million."

Guidance

ALAR

Alarum Technologies Expects Q4 Revenue Of $7.5M ±3% Vs $7.48M Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $8 to $5.

CARM

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $5

ELAB

Elevai Labs shares are trading lower after the company announced a 1-for-200 reverse stock split.

SNOW

Snowflake shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Biotech

Health Care

General

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings

Earnings Beats

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

BHVN

Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group

Contracts

SRM Entertainment Announces Order From An Orlando Theme Park For Its Misting Fans; Initial Order Of $820K For US Theme Parks And $85K For International Parks

AVXL

Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript Titled 'Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial' In A Reference Alzheimer's Disease Journal

The Lovesac Company (LOVE) Q2 2025 Earnings Call Transcript

Canaccord Genuity analyst Maria Ripps has maintained their bullish stance on LOVE stock, giving a Buy rating yesterday. Maria Ripps has given her B...

Lovesac Company: A Buy Rating Amidst Solid Growth and Innovation

Roth MKM analyst Matt Koranda maintained a Buy rating on The Lovesac Company (LOVE – Research Report) today and set a price target of $31.00. The c...

Roth MKM Keeps Their Buy Rating on The Lovesac Company (LOVE)

Lovesac: Innovative Products But Valuation Now Too High

Lovesac: With Near-Zero Growth, This Brand Is Headed For The Rocks (Rating Downgrade)

In a report released today, Michael Baker from D.A. Davidson maintained a Buy rating on The Lovesac Company (LOVE – Research Report). The company's...

D.A. Davidson Sticks to Its Buy Rating for The Lovesac Company (LOVE)

Oppenheimer analyst Brian Nagel maintained a Buy rating on The Lovesac Company (LOVE – Research Report) today and set a price target of $35.00. The...

The Lovesac Company (LOVE) Receives a Rating Update from a Top Analyst

Craig-Hallum analyst Alex Fuhrman maintained a Buy rating on The Lovesac Company (LOVE – Research Report) today. The company's shares closed yester...

The Lovesac Company (LOVE) Receives a Buy from Craig-Hallum

Q3 Earnings Outlook: Excluding Health Care, Growth Soften

La-Z-Boy: Still Comfortable With A Bullish View

AGIO

AHCO

AMBC

ASPN

ATKR

BLNK

BXMT

CALM

CLSK

CNNE

CRGX

CRGY

DBRG

FLXS

HOFT

KRUS

LOVE

Press Releases

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of The Lovesac Company (LOVE) Investigation

The Lovesac Company Announces a Five-Year Extension of Its Credit Facility and Inaugural Share Repurchase Program

Legal

The Lovesac Company Announces Second Quarter Conference Call Date

Lovesac Announces Limited-Edition Home Furnishings Collaboration with KidSuper

The Lovesac Company Reports Second Quarter Fiscal 2025 Financial Results

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of The Lovesac Company – LOVE

Lovesac Introduces AnyTable, the First Fully Customizable Table Solution Designed to Transform Your Living Space

The Lovesac Company to Host Investor Day

Lovesac Introduces Sactionals Reclining Seat: The World's Most Innovative Power Recliner

Comments

Lovesac

Notizie

Ultime notizie per Lovesac (NASDAQ:LOVE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO